

Clinical trials of rFGF-2

TrialResults-center www.trialresultscenter.org

1 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
rFGF-2 vs placebo			
TRAFFIC (Lederman) , 2002 n=127/63 follow-up: 90 days	rFGF-2 (30 microg/kg) 1 or 2 doses versus placebo	patients with intermittent claudication caused by infra-inguinal atherosclerosis	double blind

More details and results :

- cell-based therapies for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q335>

References

TRAFFIC (Lederman), 2002:

Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, Hillegass WB, Rocha-Singh K, Moon TE, Whitehouse MJ, Annex BH
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet 2002;359:2053-8
[12086757]